Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rufinamide as Adjunctive Therapy in Refractory Partial Seizures
2016-004944-12Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Focal Onset Epilepsy and epilepsy comparing Rufinamide adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Primary: Percentage change in total partial seizure frequency per 28 days.
02
Drugs
rufinamide
03
Conditions
Focal Onset Epilepsyepilepsy
Beyond the preview
Go deeper on 2016-004944-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004944-12.